N1540
NO-1886
Synonym(s):
Diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl]benzylphosphonate, Ibrolipim, OPF 009
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C19H20BrN2O4P
CAS Number:
Molecular Weight:
451.25
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
assay
≥98% (HPLC)
Quality Level
form
powder
color
off-white to pale yellow
solubility
DMSO: ≥20 mg/mL
storage temp.
2-8°C
SMILES string
CCOP(=O)(Cc1ccc(cc1)C(=O)Nc2ccc(Br)cc2C#N)OCC
InChI
1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)
InChI key
KPRTURMJVWXURQ-UHFFFAOYSA-N
Biochem/physiol Actions
Lipoprotein lipase activator. Overexpression of lipoprotein lipase in transgenic rabbits leads to increased small dense LDL in plasma and promotes atherosclerosis. Long-term administration of NO-1886 protects against the development of experimental atherosclerosis in animals.
Packaging
Packaged under nitrogen
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Masataka Kusunoki et al.
European journal of pharmacology, 668(3), 486-491 (2011-08-13)
Pioglitazone improves insulin resistance in diabetics but often causes body weight gain. The lipoprotein lipase activator NO-1886 has been shown to exert both anti-obesity and anti-insulin-resistance effects. In this study, we investigated the effect of the combined administration of pioglitazone
Masataka Kusunoki et al.
European journal of pharmacology, 668(1-2), 337-339 (2011-07-16)
It is known that postheparin plasma lipoprotein lipase (LPL) activity correlates with serum high density lipoprotein cholesterol (HDL-C) levels in humans and animals. Furthermore, LPL has been reported to cause enlargement of HDL particle size in vitro. However, these effects
Yi Liu et al.
Lipids in health and disease, 10, 117-117 (2011-07-19)
The role of renal lipoprotein lipase (LPL) per se in kidney diseases is still controversial and obscure. The purpose of this study was to observe the preventive effects of Ibrolipim, a LPL activator, on lipid accumulation and LPL expression in
Global Trade Item Number
| SKU | GTIN |
|---|---|
| N1540-5MG | 04061833057940 |
| N1540-25MG | 04061833057933 |